The coronary sinus reducer for the treatment of refractory angina by unknown
LETTER TO THE EDITOR
DOI 10.1007/s12471-016-0903-x
Neth Heart J (2016) 24:763–764
The coronary sinus reducer for the treatment of refractory angina
Y. Paz1 · A. Shinfeld2
Published online: 26 October 2016
© The Author(s) 2016. This article is available at SpringerLink with Open Access.
To the Editor,
We were very interested to read the recently published
manuscript ‘Safety and efficacy of a device to narrow
the coronary sinus for the treatment of refractory angina:
A single-centre real-world experience’ by Masieh Abawi
et al. [1]. Some people make a mistake and compare the
coronary sinus reducer (CSR) with the Beck procedure
(Beck operation), but actually the Beck procedure has
almost nothing in common with the CSR.
In the 1940s, Dr Claude Beck described two types of
coronary sinus (CS) interventions [2, 3]. The Beck I proce-
dure consisted of the following steps: 1) abrading of both
epicardium and inner pericardium. Dr Beck explained that
it produces mechanical trauma, which in turn causes in-
flammation and intercoronary arterial channels. 2) spilling
of powdered asbestos and 5 % aqueous trichloracetic acid
on the epicardium. Dr Beck explained that this produces
chemical trauma, which in turn also results in inflammation
and intercoronary arterial channels. 3) CS constriction to
a diameter of 3 mm. The Beck II procedure consisted of
a vascular graft between the descending aorta and the CS
followed by operative external constriction of the CS os-
tium a few weeks later. Both procedures needed thoracot-
 Y. Paz
pazyoav@bezeqint.net
1 General Intensive Care Unit, Tel Aviv Sourasky Medical
Center, affiliated with Sackler Faculty of Medicine, Tel Aviv
University, Tel Aviv, Israel
2 Department of Cardiac Surgery, Chaim Sheba Medical
Center, Tel Hashomer, affiliated with Sackler Faculty of
Medicine, Tel Aviv University, Tel Aviv, Israel
omy and as can be seen have very little in common with
the CSR.
May we add our personal experience with the CSR: In
the mid-1990s we tested a new strategy supporting the is-
chaemic myocardium. This strategy included: 1) catheteri-
sation of the coronary venous system rather than catheteri-
sation of the coronary arteries, and 2) reduction of the CS
effective cross area, as opposed to expansion of a narrowed
coronary artery. At that time, the main concept behind this
strategy was only to rebuild retrograde coronary pressure
that would be attenuated by the atherosclerotic disease. In
order to test this strategy, we designed and manufactured
the first CSR stent. In a preliminary non-ischaemic pig
model we succeeded in increasing the mean CS pressure
from 7.0 to 24.6 mm Hg (p = 0.011) immediately after
CSR stent deployment. Further studies in a non-ischaemic
pig model were devoted to macroscopic and histological
investigations of the treated hearts, in particular investigat-
ing whether any structural or histological damage, such as
an infarct, had occurred after reducer implantation. While
looking for such damage, these studies revealed that 8 to
12 weeks of CS narrowing produced macroscopic epicar-
dial and intramyocardial new blood vessels – neovasculari-
sation. Histopathological analysis described these findings
as follows: significant proliferation of small to medium-
sized vessels, containing smooth muscle representing coro-
nary collaterals. This was evident in almost all specimens,
representing various myocardial anatomical areas, includ-
ing specimens from the anterior and mid-posterior wall.
According to these unpredicted neovascularisation findings
after reducer implantation in a non-ischaemic pig model,
we created the name ‘Neovasc’ for this novel CSR stent.
764 Neth Heart J (2016) 24:763–764
Conflict of interest Y. Paz and A. Shinfeld are the inventors of the
Neovasc Coronary Sinus Reducer Stent. Currently neither of the au-
thors have any commercial or other association with the company
whose product is the subject of the review or with a company that
manufactures comparable products.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Abawi M, Nijhoff F, Stella PR, et al. Safety and efficacy of a
device to narrow the coronary sinus for the treatment of refrac-
tory angina: a single-centre real-world experience. Neth Heart J.
2016;24(9):544–51. doi:10.1007/s12471-016-0862-2.
2. Beck CS, Leighninger DS. Scientific basis for the surgical treatment
of coronary artery disease. JAMA. 1955;159(13):1264–71. doi:10.
1001/jama.1955.02960300008003.
3. Beck CS, Leighninger DS. Operations for coronary artery dis-
ease. JAMA. 1954;156(13):1226–33. doi:10.1001/jama.1954.
02950130006002.
